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Abstract
Angiogenesis, the formation of a new blood supply, is
an essential step in tumorigenesis. Although vascular
endothelial growth factor (VEGF) is known to be a very
potent angiogenic factor in most solid tumors, little is
known about its production and regulation in pituitary
adenomas. We have investigated basal and stimulated
VEGF production by rodent pituitary tumor cells
(mouse corticotrope AtT20, rat lactosomatotrope GH3,
mouse gonadotrope ·T3-1 and mouse folliculostellate
TtT/GF cells), and by hormone-inactive (27), cortico-
trope (9), lactotrope (3) and somatotrope (21) human
pituitary adenoma cell cultures. All 4 pituitary cell lines
secreted VEGF, which in the case of AtT20, GH3 and
TtT/GF cells was inhibited by approximately 50% by
dexamethasone. TtT/GF cells were the most responsive
to the different stimuli used since basal values were
augmented by pituitary adenylate cyclase activating
polypeptide-38 (PACAP-38), interleukin-6 (IL-6), trans-
forming growth factor-· (TGF-·), IGF-I and the somato-
statin analogue ocreotide. However, in GH3, AtT20 and
·T3-1 cells, basal VEGF levels where not enhanced with
any of the stimuli tested. The majority of the human
adenomas tested (92%) basally secreted measurable
VEGF which was inhibited by dexamethasone in most
cases (84%). VEGF levels were increased in hormone
inactive adenomas, somatotrope tumors and prolacti-
nomas by TGF-·, PACAP-38, and 17ß-estradiol, respec-
tively. In conclusion, pituitary tumor cells are capable of
producing VEGF which may be involved in tumoral
angiogenesis. Our results concerning the suppression
of VEGF by dexamethasone suggest that glucocorti-
coids may have anti-angiogenic properties and there-
fore therapeutic relevance for the treatment of pituitary
adenomas.
Copyright © 2001 S. Karger AG, Basel
Introduction
As for any solid tumor, neovascularization of pituitary
adenomas is required in order to supply the tumor cells
with nutrients and oxygen. In addition, the generation of a
direct arterial blood supply during neovascularization has
fundamental functional consequences for endocrine ade-
noma cells, since it uncouples the pituitary tumor cells
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from the portal blood vessel system and thus from hypo-
thalamic control [1–3]. Anti-angiogenic treatment strate-
gies for pituitary adenomas might be helpful to reduce this
direct arterial blood supply, and, in this way, restore in
particular the inhibitory influences of the hypothalamus
on the endocrine tumor cells. VEGF is considered to be
the most important angiogenic factor involved in the
neovascularisation of solid tumors. To date, anti-angio-
genic strategies in the treatment of tumors mainly focus
on the suppression of VEGF production, or the down-reg-
ulation of its receptors [4–6].
Vascular endothelial growth factor (VEGF) is a ho-
modimeric glycosylated protein of 46–48 kD (24 kD sub-
units) [6] produced by numerous cell types including
fibroblasts [7, 8], mesangial cells [9] and keratinocytes
[10]. As a result of alternative splicing VEGF occurs in
several isoforms which in humans are 121, 145, 165, 189
and 206 amino acids long [11–13]. VEGF has been dem-
onstrated to have many biological functions such as
enhancing vascular permeability [5] and increasing me-
tastases formation [14]. However, its major function ap-
pears to be that of angiogenesis in tumorigenesis [15],
wound healing [16], embryo organ development [16, 17]
and during reproduction functions in the adult [18].
VEGF has two structurally related tyrosine kinase
receptors, flt-1 and flk-1 (KDR), which appear to have
quite different functions. Flk-1 has been demonstrated to
be involved in actin re-organization [19], chemotaxis [19],
blood island formation and vasculogenesis in mouse em-
bryos [20], whereas flt-1 has been reported to be involved
in nitric oxide production [21] and the organisation of the
embryonic vasculature [22].
VEGF has been demonstrated to be expressed in the
normal pituitary only in folliculostellate (FS) cells [23,
24]. In a small number of pituitary adenomas studied,
VEGF mRNA and protein expression could also be
detected by PCR [25] and by immunohistochemistry [26],
but at present it is not clear by which cell types VEGF is
produced inside the tumors. VEGF has also been found in
corticotrope AtT20 [27] and lactosomatotrope GH3 cells
[28]. In the latter, VEGF production has been demon-
strated to be stimulated by estrogen [28]. VEGF expres-
sion is enhanced in Fischer 344 rats during the develop-
ment of estrogen-induced prolactinomas [29, 30]. In fol-
liculostellate TtT/GF pituitary tumor cells, IL-6 and
PACAP-27/38 stimulated VEGF release, whereas it was
suppressed by dexamethasone [31]. VEGF secretion by
rat pituitary cell cultures was regulated by IL-6, PACAP
and dexamethasone in an identical manner [31], suggest-
ing that the regulation of VEGF production in normal and
tumorous FS cells is very similar. However, apart from
these few studies, little is known concerning the regulation
of VEGF within the normal pituitary and especially in
pituitary tumors. Therefore, we have determined basal
VEGF levels in 4 different rodent pituitary tumor cell
lines and in different types of pituitary adenomas and
have studied VEGF secretion in response to an array of
different substances that are known or thought to affect
pituitary adenoma development.
Material and Methods
Patients
The present study was approved by the ethics committee of the
Max Planck Institute of Psychiatry (Munich, Germany) and was
undertaken after informed consent was received from each patient.
Pituitary adenomas were diagnosed by plasma pituitary hormone
testing and magnetic resonance imaging as previously described [32–
34]. The characteristics of the tumors, divided according to their clin-
ical symptoms, are shown in tables 1 and 2. No hormonal excess was
found in any of the patients with clinically inactive adenomas
although routine immunohistochemical evaluation showed immuno-
reactivity for LH, FSH or ·-subunit in cellular subsets in most of
these adenoma tissues (not shown). Elevated GH (range 19–97 Ìg/l)
and IGF-I (range 844–2,737 Ìg/l) serum concentrations were found
in the group of patients with acromegaly. In some of the correspond-
ing tumor tissues, proportions of cells were also immunopositive for
PRL. Patients with corticotrope adenomas presented classical symp-
toms of Cushing's disease due to elevated ACTH (range 16.4–
79.1 nmol/l) and cortisol (range 416–1,089 nmol/l) levels. Cortico-
trope adenoma tissue was found to be immunoreactive only for
ACTH. Elevated PRL serum levels (range 120–3,700 Ìg/l) were
found in patients with lactotrope tumors. Two of the 3 prolactinomas
had to be operated on because they were nonresponsive to dopamine
agonist treatment; in the third case surgery was performed due to
compliance problems. Only PRL immunoreactivity was detected by
immunohistochemistry in the corresponding adenoma tissues.
Materials
Cell culture materials and reagents were obtained from Gibco
(Karlsruhe, Germany), Falcon (Heidelberg, Germany), Nunc (Wies-
baden, Germany), Seromed (Berlin, Germany), Flow (Merkenheim,
Germany) and Sigma Chemicals (St. Louis, Mo., USA). Mouse IL-6
was obtained from Roche Molecular Biochemicals (Mannheim, Ger-
many). PACAP-38, IGF-I, and TGF-· were obtained from Bachem
(Bubendorf, Switzerland). Dexamethasone and 17ß-estradiol (E2)
were obtained from Sigma Chemicals, ocreotide was kindly provided
by Novartis (Basel, Switzerland). Bromocriptine was purchased from
RBI (Natick, USA).
Pituitary Cell Line Culture
·T3-1, GH3, TtT/GF and AtT20 cells were plated into 48 wells.
All the cells were grown in Dulbecco’s modified Eagle’s medium (pH
7.3) supplemented with 10% FCS, 2.2 g/l NaHCO3, 10 mM HEPES,
2 mM glutamine, 105 U/l penicillin-streptomyocin, and 2.5 mg/l
amphotericin; however, the TtT/GF and ·T3-1 cell medium was fur-
ther supplemented with 30 pM tri-iodothyronine, 5 mg/l transferrin,
HI 1
S 1
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Table 1. Characteristics of clinically hormone-inactive pituitary
adenomas (HI 1 to HI 27)
Tumor Sex/age Sizea/invasiveb VEGFc
M/77 macro/yes 13.56B1.15
HI 2 M/75 macro/yes 2.72B0.08
HI 3 F/63 macro/no 2.00B0.08
HI 4 M/74 macro/no 0.95B0.06
HI 5 F/17 macro/no 1.59B0.04
HI 6 M/54 macro/no 0.24B0.03
HI 7 F/64 macro/yes 0.07B0.01
HI 8 F/50 macro/yes 0.14B0.01
HI 9 M/82 macro/no 0.40B0.03
HI 10 M/82 macro/yes 1.47B0.01
HI 11 M/50 macro/yes 7.85B0.40
HI 12 M/35 macro/yes 0.88B0.08
HI 13 M/78 macro/no 0.53B0.01
HI 14 M/52 macro/no 0.07B0.01
HI 15 M/76 macro/yes 1.07B0.13
HI 16 M/39 macro/no 0.09B0.01
HI 17 F/31 macro/no 2.55B0.003
HI 18 M/49 macro/no nd
HI 19 F/64 macro/no 0.23B0.02
HI 20 M/59 macro/no 1.44B0.14
HI 21 M/59 macro/no 0.70B0.06
HI 22 F/72 macro/no 0.92B0.09
HI 23 M/60 macro/no 1.73B0.20
HI 24 M/74 macro/no 2.54B0.09
HI 25 M/41 macro/no 1.78B0.01
HI 26 M/53 macro/no 0.50B0.06
HI 27 M/34 macro/no 0.93B0.06
a Tumors larger than 1 cm in diameter were designated as mac-
roadenomas.
b Positive invasion indicates tumor extension within the cavernous
sinus and/or the sphenoid sinus.
c Basal VEGF secretion in vitro expressed as pg/1,000 cells/24 h.
nd = Not detectable.
Table 2. Characteristics of clinically hormone active somatotrope
(S1–S21), corticotrope (C1–C9) and lactotrope (L1–L3) pituitary
adenomas
Tumor Sex/age Sizea/invasiveb VEGFc
F/26 macro/yes 1.16B0.06
S 2 M/31 macro/yes 5.02B0
S 3 F/55 macro/yes 0.87B0.05
S 4 M/35 macro/yes 1.02B0.05
S 5 F/45 macro/no 3.42B0.18
S 6 F/42 macro/yes 0.09B0
S 7 M/32 micro/no 0.18B0.01
S 8 M/19 macro/no 1.29B0.11
S 9 F/52 macro/no 0.52B0.04
S 10 F/35 macro/yes 1.36B0.15
S 11 M/29 macro/no 0.40B0.07
S 12 F/65 macro/yes nd
S 13 M/64 micro/no nd
S 14 M/28 macro/yes nd
S 15 M/23 micro/no 0.28B0.02
S 16 M/55 macro/no 0.23B0.11
S 17 F/48 micro/no 1.06B0.004
S 18 F/58 micro/no nd
S 19 F/70 macro/no 0.53B0.06
S 20 F/67 micro/no 0.78B0.12
S 21 F/52 macro/yes 0.26B0.02
C 1 F/24 micro/no 0.43B0.03
C 2 F/21 micro/no 1.83B0.08
C 3 F/22 micro/no 0.05B0.004
C 4 F/33 micro/no 0.08B0.02
C 5 M/29 micro/no 1.18B0.08
C 6 F/54 micro/no 0.05B0.004
C 7 F/38 micro/no 0.11B0.01
C 8 M/45 micro/no 0.21B0.03
C 9 F/41 macro/no 0.45B0.06
L1 F/25 macro/no 12.73B0.88
L 2 F/43 macro/no 0.73B0.03
L 3 M/29 macro/no 0.03B0.004
a Tumors larger than 1 cm in diameter were designated as mac-
roadenomas.
b Positive invasion indicates tumor extension within the cavernous
sinus and/or the sphenoid sinus.
c Basal VEGF secretion in vitro expressed as pg/1,000 cells/24 h.
nd = Not detectable.
20 mg/l sodium selenium, essential amino acids and minimal essen-
tial vitamins. The cells were grown at 37°C with 5% CO2 in a humid
incubator.
Primary Cell Culture of Pituitary Adenomas
Pituitary adenoma cell culture was performed as previously
described [34]. In brief, the tumors where washed and then treated
for approximately 1 h with collagenase at 37°C followed by mechani-
cal agitation. Once the tumor had been dissociated the resultant cells
where washed by repeated centrifugation. The pellet was resupended
in medium and the cell counts and viability determined using acri-
dine orange and ethidium bromide. 100,000 cells per well were
plated into 48-well plates and cultivated in 0.5 ml/well of D-
Val-MEM medium (pH 7.3) supplemented with 10% FCS, 2.2 g/l
NaHCO3, 10 mM HEPES, 2 mM glutamine, 105 U/l penicillin-strep-
tomyocin, 2.5 mg/l amphotericin, 30 pM tri-iodothyronine, 5 mg/l
transferrin, 20 Ìg/l sodium selenium, essential amino acids and min-
imal essential vitamins. D-Val-MEM medium was used to suppress
growth of fibroblasts [34].
Stimulation and VEGF Determination
When the tumor cell lines were nearly confluent, or in case of the
adenoma cell cultures 2 days after plating, the cells were washed once
with phosphate-buffered saline (PBS) and then pretreated for 24 h in
the appropriate cell culture medium without FCS (0.5 ml medium
per well). Following the pretreatment period, the cells were treated in
98 Neuroendocrinology 2001;74:95–105 Lohrer/Gloddek/Hopfner/Losa/Uhl/
Pagotto/Stalla/Renner
Fig. 1. VEGF mRNA detected by nonquantitative RT-PCR in pitu-
itary tumor cell lines (AtT20, GH3, ·T3-1, TtT/GF) and in fetal
mouse tissue (+ve control). The expected 204 kb cDNA band is
visualized by ethidium bromide staining. In the absence of specific
primers (H2O) no PCR product was present.
triplicate with the following substances diluted in fresh serum-free
medium (0.5 ml/well): 10–9 to 10–6 M dexamethasone or bromocrip-
tine, 10–10 to 10–7 M E2, 10–9 to 10–7 M PACAP-38, ocreotide or
TGF-·, 0.1 to 10 ng/ml IL-6 and 0.2 ng/ml to 20 ng/ml IGF-I. Cells
were treated with the substances for 24 h since no short-term stimula-
tion of VEGF was observed in a previous study [31]. The supernatant
(0.5 ml) was then collected from the wells and the secreted VEGF
isoforms, among them the dominating human VEGF165 or mouse/
rat VEGF164, were measured in terms of pg/ml using specific ELISA
assay kits for human and mouse/rat VEGF (R&D Systems, Wiesba-
den, Germany) [31], respectively. The detection limit of the VEGF
ELISA was 3 pg/ml for both mouse/rat and human VEGF. Intra- and
inter-assay coefficients were 4.7 and 6.4% for the mouse/rat VEGF
ELISA and 5.1 and 7.3% for the human VEGF ELISA. To exclude
the possibility that variations in the concentration of VEGF (mea-
sured as pg/ml) in the cell culture supernatants might reflect varia-
tions in cell number, the cells in each well were counted and VEGF
secretion was calculated as pg per 1,000 cells per 24 h.
Cell Counts
The cell monolayers were treated for 5–10 min with 400 Ìl tryp-
sin/EDTA at 37°C, the enzymatic reaction was stopped with 100 Ìl
FCS, and the number of cells were determined as previously
described [35] in each well using an adapted Coulter counter.
Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
For RT-PCR, total cellular RNA was isolated from the cell lines
and from mouse fetal tissue by guanidinium isothiocyanate followed
by the phenol-chloroform method [36]. For VEGF mRNA detection,
the C therm. polymerase one-step RT-PCR kit (Roche Molecular
Biochemicals, Mannheim, Germany) was used following the manu-
facturer's instructions. In brief, a mixture of 0.4 mM of each deoxy-
nucleoside triphosphate, 7% dimethylsulfoxide (DMSO), 5 mM
dithiothreitol (DTT), 20 U RNase inhibitor, 2 ÌM sense and 2 ÌM
antisense VEGF primer and 1 Ìg total cellular RNA in a final volume
of 25 Ìl was carefully mixed on ice with 25 Ìl of a solution containing
C therm. polymerase in RT-PCR buffer. The mixture was then
placed in a thermocycler (Techne, Cambridge, UK) to perform
reverse transcription at 64°C for 30 min followed by a 35-cycle PCR,
each cycle consisting of denaturation at 94°C for 45 s, annealing of
primers at 60°C for 45 s, and chain extension at 72°C for 1 min.
Amplified products were electrophoresed in 1.8% agarose gel and
stained with ethidium bromide.
Specific primers to detect murine VEGF mRNA were con-
structed according to the published DNA sequence [36] (GenBank
accession number: S38100). The VEGF primers (5) primer: 5)-CCT
GGT GGA CAT CTT CCA GGA GTA CC-3); 3)primer: 5)-TGT
GCT GTA GGA AGC TCA TC-3)) generated a PCR amplification
product of 204 bp in length.
Statistics
The individual experiments were performed with triplicate wells
and analysis of variance (ANOVA) in combination with Scheffe's test
was used for statistics. The data are expressed as mean B SE. Differ-
ences between the tumor types were assessed using the Mann-Whit-
ney U test.
Results
VEGF Secretion and Regulation in Pituitary Tumor
Cell Lines
All four cell lines synthesized VEGF mRNA as demon-
strated by RT-PCR (fig. 1) and basally secreted VEGF
protein. The highest VEGF production expressed in
terms of pg/1,000 cells/24 h was observed in AtT20 cells
(2.43 B 1.07) followed by TtT/GF cells (1.51 B 0.71),
and then GH3 cells (0.36 B 0.10), and finally ·T3-1 cells
(0.21 B 0.04) which produced the least. The relatively
high SE values are due to the fact that basal VEGF secre-
tion data were pooled from different experiments per-
formed with different batches or passages of the cell lines.
VEGF secretion values for the individual experiments
indicated below, and shown in figures 2 and 3, mostly
exhibited SE values of less than 15% of the mean.
Dexamethasone dose-dependently inhibited VEGF in
AtT20, GH3 and TtT/GF cells, but had no effect on basal
VEGF production in ·T3-1 (fig. 2). Half-maximal inhibi-
tion of VEGF secretion was achieved with 10–8 M dexa-
methasone. Maximum inhibitory effects on VEGF pro-
duction were induced by 10–7 M dexamethasone whereas
10–6 M dexamethasone did not further significantly in-
hibit VEGF release. The glucocorticoid receptor antago-
nist RU486 reversed the inhibitory action of dexametha-
sone confirming the specificity of the glucocorticoid inhi-
bition of VEGF production.
Figure 3 summarizes the response of VEGF to other
stimuli tested in rodent pituitary cell lines. Although dose
response studies have been performed for all the test sub-
stances in all of the cell lines, only the effects of the maxi-
mum concentrations of the stimuli are shown. VEGF
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Fig. 2. Suppression of VEGF production by
dexamethasone in pituitary tumor cell lines.
Dexamethasone dose-dependently inhibited
VEGF secretion in folliculostellate TtT/GF
cells (a), corticotrope AtT20 cells (b), and
lactosomatotrope GH3 cells (c), whereas
VEGF production by gonadotrope ·T3-1
cells was not affected. The glucocorticoid
receptor antagonist RU486 (10–7 M ) itself
did not affect VEGF inhibitory action of
10–8 M dexamethasone. Treatment period
was 24 h in all experiments. Values (mean B
SE) are expressed as % of basal (= 100%)
secretion. * p ! 0.05; ** p ! 0.01; *** p !
0.001.
secretion by the endocrine pituitary cell lines (·T3-1,
AtT20 and GH3 cells) was not affected by any stimuli
tested as only a few substances slightly, but not signifi-
cantly, inhibited or stimulated VEGF production in some
of the endocrine pituitary tumor cell lines (fig. 3). Treat-
ment of GH3, AtT20 and ·T3-1 cells with 10–9 to 10–7 M
TRH, CRH and LHRH did not affect basal VEGF secre-
tion (data not shown).
However, TtT/GF cells were remarkably responsive to
stimulation. PACAP-38 (10–7 M) and IL-6 (10 ng/ml)
strongly augmented VEGF levels to 339 B 69% and 178
B 23% of basal, respectively (fig. 3a, d). Dose-dependent
stimulation of VEGF production by PACAP and IL-6 in
TtT/GF cells has already been shown in a previous study
[31] and, therefore, is not documented again in the
present manuscript. Significant increases in VEGF secre-
tion were also observed after stimulating TtT/GF cells
with 20 ng/ml IGF-I (173.4 B 13.4%; fig. 2c), 10–7 M
TGF-· (161.2 B 17.0%; fig. 2f) and 10–7 M octreotide
(168.9 B 9.0%; fig. 2e). Lower concentrations of these 3
substances, slightly but not significantly, stimulated
VEGF secretion by TtT/GF cells. Both bromocriptine
and E2 did not affect VEGF production by TtT/GF cells
at any concentration tested.
VEGF Secretion and Regulation in Human Pituitary
Adenoma Cell Cultures
Basal VEGF levels for each tumor are presented in
tables 1 and 2. In vitro, all 9 corticotrope tumors and all 3
prolactinomas produced basal VEGF, whereas 1 of the 27
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Fig. 3. Regulation of VEGF release from gonadotrope ·T3-1 cells (open bars), corticotrope
AtT20 cells (horizontal stripes), Lactosomatotrope GH3 cells (vertical stripes) and folliculo-
stellate TtT/GF cells (black bars). Cells were treated for 24 h with stimuli at different concen-
trations as indicated in ‘Materials and Methods’, but only the VEGF values in response to
10–7 M PACAP-38 (a), 10–6 M bromocriptine (b), 20 ng/ml IGF-I (c), 10 ng/ml IL-6 (d), 10–7
M octreotide (e), 10–7 M TGF-· (f), and 10–7 M 17ß-estradiol (g) are shown. Values (mean B
SE) are expressed as % of basal (= 100%) VEGF secretion. * p ! 0.05; *** p ! 0.001.
Fig. 4. Comparison of the basal VEGF pro-
duction (expressed as ng VEGF per 1,000
cells per 24 h; see tables 1 and 2) by nonfunc-
tioning (NF), somatotrope (Acro) and corti-
cotrope (Cush) pituitary adenomas. VEGF
values for prolactinomas have been excluded
in this figure since too few cases with ex-
tremely heterogeneous basal VEGF secre-
tion had been studied (table 2). The mean
VEGF values of the individual tumor cell
cultures are shown without SE bars. Differ-
ences in the VEGF production among the
different adenoma types were not signifi-
cant.
hormone inactive adenomas (4%) and 4 of the 21 somato-
trope tumors (19%) had no detectable basal VEGF. The
mean basal VEGF values for the hormone inactive, soma-
totrope and corticotrope tumors (too few lactotrope ade-
nomas were studied to perform appropriate statistics)
were 1.74 B 0.54, 0.88 B 0.27 and 0.49 B 0.21 pg/1,000
cells/24 h, respectively (fig. 4). However, due to the wide
range in values between the individual tumors, there was
no significant difference between the different tumor
types. Furthermore, no significant differences in the basal
VEGF secretion were found between micro- and ma-
croadenomas or between invasive and noninvasive tu-
mors (data not shown).
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Fig. 5. Suppression of VEGF production by
dexamethasone in human pituitary adeno-
ma cultures. Results of three representative
tumor cell cultures (somatotrope adenoma
S9, corticotrope adenoma C2 and hormone-
inactive adenoma HI11), in which VEGF
secretion was dose-dependently inhibited by
dexamethasone during a 24-hour treatment
period, are shown. * p ! 0.05; ** p ! 0.01;
*** p ! 0.001.
Fig. 6. Effect of dexamethasone (10–6 M ) on VEGF secretion by pituitary adenoma cell cultures. Cells were treated
for 24 h. Values (mean B SE) are expressed as % of basal (= 100%). * p ! 0.05; ** p ! 0.01; *** p ! 0.001.
In the results of the stimulation experiments which are
shown in figures 5 and 6 and in table 3, only the tumors
which had measurable VEGF are taken into consider-
ation. Since basal VEGF secretion by the tumors was
extremely heterogeneous, values are expressed as % of
basal ( = 100%). Due to the limited amount of tumor tis-
sue available, in most cases VEGF stimulation tests could
not be performed with all stimuli in parallel. Because
rodent pituitary cell lines were most responsive to gluco-
corticoid treatment, the effect of dexamethasone on
VEGF secretion was studied in as many pituitary adeno-
mas as possible. In about half of the tumors treated with
dexamethasone, dose-response studies were performed
(representative results are shown in figure 5) whereas the
IL-6 (10 ng/ml)
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Table 3. Alterations in VEGF production (% of basal) by human pituitary adenoma cell cultures in response to
different stimuli
Stimulus Adenomas
hormone inactive somatotrope prolactinoma corticotrope
90.4B7.8 (10) 101.4B14.5 (5) 106.0 (1) 119.1B12.7 (5)
PACAP-38 (10–1 M) 107.0B16.5 (6) 138.7B10.4 (3)* 126.1B18.9 (2) 103.3 (1)
IGF-I (20 ng/ml) 103.5B8.3 (3) 109.4B12.1 (10) 108.8B6.2 (2) 113.7B4.9 (3)
Octreotide (10–7 M) 95.7B2.5 (2) 98.5B16.7 (6) 93.7 (1) 102.8B12.1 (4)
Bromocriptine (10–6 M) 122.9B11.1 (5) 116.5B14.0 (4) 93 (1) 110 (1)
E2 (10–7 M) 110.2B12.0 (7) 87.8B28.1 (3) 141.8B4.8 (2)** –
TGF-· (10–7 M) 136.7B8.7 (7)** 116.8B8.0 (6) 120 (1) 127.7B28.2 (3)
* p ! 0.05, ** p ! 0.01.
remaining adenomas were treated only with two concen-
trations (10–8 M, 10–6 M ) or the highest dose of dexa-
methasone. Figure 6 summarizes the VEGF response to
treatment with 10–6 M dexamethasone, which significant-
ly inhibited VEGF release in 31 of 37 adenomas (84%).
Results from dose-response studies in dexamethasone-
responsive adenoma cell cultures showed a similar
VEGF-inhibitory pattern (fig. 5) as observed in pituitary
tumor cell lines.
Most of the other stimuli tested, did not affect VEGF
secretion in different types of adenomas. Average VEGF
secretion values are listed in table 3.
Only in the hormone inactive tumors did TGF-· sig-
nificantly increase basal VEGF levels to 136.7 B 8.7%
(p ! 0.01, n = 7). However, although TGF-· enhanced
VEGF secretion in all these tumors, only in 4 of 7 were the
increases significant. Two of 3 of the somatotrope tumors
treated with PACAP-38 had significantly elevated levels
of VEGF. The mean of PACAP-induced VEGF produc-
tion, expressed as % of basal, was 138.7 B 10.4 (p ! 0.05).
E2 significantly increased VEGF levels in the prolactino-
mas (141.8 B 4.8%; p ! 0.01). Both tumors tested
responded to E2 with significantly enhanced production
of VEGF.
Apart from the tumor types indicated above, TGF-·,
PACAP-38 and E2 did not affect VEGF production by
any other adenoma type. Octreotide, bromocriptine, IL-6
and IGF-I had no significant effect on VEGF secretion in
all adenoma types (table 3).
Discussion
Although pituitary adenomas are normally less well
vascularized than normal anterior pituitary [37], there is
no doubt that neovascularization is essential for pituitary
tumor formation. In the present work the secretion and
regulation of the most potent angiogenic factor, VEGF,
was studied for the first time in pituitary tumor cell lines
and a large number of pituitary adenomas in vitro.
Whereas in normal pituitary VEGF has been reported to
be produced only by FS cells [23, 24], it seems that during
transformation endocrine pituitary tumor cells acquire
the ability to produce VEGF, since in contrast to the cor-
responding normal endocrine cell types, corticotrope
AtT20 and lactosomatotrope GH3 pituitary tumor cell
lines basally synthesized and released VEGF. Since FS
cells are rarely found in adenomas (see below) and
because intratumoral endothelial cells represent a target
but not a source of VEGF within solid tumors [6], pitu-
itary adenoma cells seem to be responsible for VEGF pro-
duction in the pituitary tumor cell cultures. Although the
source of VEGF in adenomas needs to be identified more
precisely in future studies, our results suggest that endo-
crine pituitary tumor cells may be involved in the angio-
genetic process, which is essential for tumor progression.
Rodent endocrine pituitary cell lines (AtT20, GH3,
·T3-1) and human pituitary adenoma cells produced
extremely variable amounts of VEGF under basal condi-
tions. However, in vitro VEGF production by human
adenoma cells did not correlate with size or the invasive
character of the tumors. None of the substances that are
clinically used to suppress expansion of some types of
pituitary adenomas, such as the somatostatin analogue
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octreotide, or the dopamine agonist bromocriptine, inhib-
ited VEGF production in any of the adenoma types or
endocrine cell lines tested, although the presence of func-
tional receptors in these tumors or cell lines has previous-
ly been demonstrated [32–34, 38–41]. This indicates that
these compounds do not mediate tumor shrinkage via
suppression of VEGF-driven angiogenesis.
In contrast, as has already been shown in other types of
solid tumors [42, 43], glucocorticoids can have an anti-
angiogenic property since in most human adenomas
(84%) as well as in AtT20 and GH3 cell lines VEGF
release was suppressed by dexamethasone. Our observa-
tion that glucocorticoids are potent inhibitors of VEGF
production in vitro is highly relevant especially with
respect to corticotrope adenoma development in vivo.
Since serum cortisol levels are elevated in patients with
Cushing's disease, VEGF production and the subsequent
angiogenesis in the corticotrope adenomas could be sup-
pressed in vivo. This could be one explanation for the
microadenomatous phenotype of these tumors. On the
other hand, the development of large corticotrope Nelson
tumors after bilateral adrenalectomy may in part be a con-
sequence of enhanced angiogenesis due to the removal of
the inhibitory influence of glucocorticoids on VEGF pro-
duction.
Autonomous VEGF production by endocrine pituita-
ry cell lines and adenoma cells was poorly stimulated.
PACAP-38 was found to stimulate VEGF production by
somatotrope adenoma cells and TGF-· enhanced VEGF
release from nonfunctioning tumor cells, indicating that
these factors might play a role in some types of adenomas.
However, since only a few adenomas were studied, more
work is needed to confirm this hypothesis. Neither IGF-I
that is enhanced in patients with somatotrope adenomas,
nor IL-6 that is known to stimulate VEGF production in
some types of tumor cells [44] and is intrinsically pro-
duced by many pituitary adenomas [45–47], were able to
stimulate VEGF production by pituitary adenoma cells.
In contrast to adenoma cells, VEGF production by fol-
liculostellate TtT/GF pituitary cells was strongly en-
hanced by PACAP-38, TGF-·, IL-6 and IGF-I. There-
fore, these substances probably affect pituitary adenoma
vascularisation by another mechanism in which FS cells
play an important role. FS cells are not or only rarely
found in pituitary adenomas but accumulate in a transi-
tion zone at the boundary of the tumors [48–50]. It is pos-
sible that during tumorigenesis substances that are pro-
duced by tumor cells themselves (IL-6, TGF-·) [45–47,
51, 52], or by the hypothalamus (PACAP-38), or that are
elevated in the blood (IGF-I in acromegalic patients) may
stimulate VEGF production by FS cells within this transi-
tion region. The FS cell-derived VEGF could then diffuse,
or be carried in the blood supply, to the tumor where it
could cause the generation of new blood vessels. There-
fore, during initiation of tumor formation, and especially
in microadenomas, the edge of the adenoma could repre-
sent the major site of initiation and regulation of angio-
genesis. This concept is similar to the model proposed by
Fukumara et al. [53] where they speculated that fibro-
blasts on the tumor periphery are the most important
source of VEGF during formation of some types of
tumors.
High estrogen levels are considered to be responsible
for pituitary hyperplasia in pregnant females and are
thought to be involved in prolactinoma development [54].
We could not confirm a previous report that E2 stimulates
VEGF production by lactosomatotrope GH3 cells [28],
but we have been able to demonstrate that E2 augments
VEGF levels in prolactinoma tumor cell preparations.
This could be part of the mechanism by which estrogen
causes pituitary hyperplasia and prolactinoma formation.
Our observation is in agreement with the findings of
Banerjee et al. [29] who demonstrated in vivo that estro-
gen stimulates VEGF production, and increases VEGF
receptors expression during estrogen-induced prolactino-
ma formation in Fischer 344 rats. However, VEGF regu-
lation by E2 needs to be studied in more lactotrope adeno-
mas, to confirm our speculation that E2 is involved in
prolactinoma neovascularisation.
In summary, we have demonstrated that pituitary ade-
noma cells produce extremely variable amounts of VEGF
in vitro. The heterogeneity in VEGF production by pitu-
itary adenomas might reflect the degree of intratumoral
vessel formation which may correlate with the dynamics
of pituitary tumor progression. Our results concerning the
suppression of VEGF by dexamethasone suggest that glu-
cocorticoids may have anti-angiogenic properties and,
therefore, therapeutic benefit in the treatment of some
types of pituitary adenoma.
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